Pelvital has announced the publication of a landmark review paper in Continence Reports highlighting the efficacy of transvaginal mechanotherapy as a first-line treatment for stress urinary incontinence (SUI). The study found that the treatment, which promotes muscular, cellular, and neuromuscular rehabilitation, delivered significant improvements in both pad weight reduction and quality of life.
The research indicates that outcomes were superior to traditional pelvic floor muscle training and comparable to surgical interventions, while offering a non-invasive alternative that can be used at home. The treatment works by superimposing mechanotherapy on pelvic floor muscle training to increase efficacy and reduce treatment time.
“I am proud to be a part of this crucial article that highlights the evidence behind transvaginal mechanotherapy as a groundbreaking advancement for the millions of women struggling with stress urinary incontinence,” says Leah Fulker, DPT and Pelvital Patient Support Manager. “There is a significant gap in care for women with urinary incontinence, leaving many without access to effective treatment options. By prescribing this first-line conservative treatment that is used in the home, Family Medicine and OB/Gyn physicians can bridge this gap, providing women with a safe, effective, and accessible solution that delivers lasting results and significantly improves quality of life.”
Pelvital’s FDA-cleared product Flyte is currently the only in-home device delivering mechanotherapy to the pelvic floor. “Pelvital is committed to advancing the science of women’s health and expanding access to effective, evidence-based treatments,” says Lydia Zeller, CEO of Pelvital. “This paper validates the effectiveness of transvaginal mechanotherapy as a first-line treatment and reinforces our mission to provide clinicians and women with a proven, accessible, non-invasive solution.”
